Atea’s HCV Combo Shows No Interactions; AT-587 Displays 150× HEV Potency
AVIR•Phase 1 data show Atea’s bemnifosbuvir and ruzasvir combination can be co-administered with omeprazole, digoxin and rosuvastatin without clinically meaningful interactions, reinforcing a best-in-class HCV profile. Preclinical AT-587 data show 30-150 × in vitro potency versus sofosbuvir and ribavirin and in vivo efficacy in HEV 3 models, enabling first-in-human studies.
1. Phase 1 DDI Results for BEM/RZR
In a Phase 1 trial in healthy adults, Atea administered the fixed-dose combination of bemnifosbuvir and ruzasvir with omeprazole (20 mg and 40 mg), digoxin and rosuvastatin. Omeprazole 20 mg had no impact on plasma exposure, 40 mg caused only slight reduction, and co-administration with digoxin or rosuvastatin produced geometric mean ratios below 2, indicating no dose adjustments required and favorable safety.
2. Preclinical AT-587 Potency and Efficacy
AT-587 demonstrated 30-150 × greater in vitro inhibition of HEV replication versus sofosbuvir and ribavirin without detectable toxicity, and showed significant viral reduction in HEV-3 infected gerbil models, supporting its potential as a first-in-class oral HEV therapy.
3. Upcoming Clinical Milestones
Atea plans to report topline Phase 3 data from its C-BEYOND and C-FORWARD HCV trials, and advance AT-587 into a first-in-human study in mid-2026, aiming to address unmet needs in HCV and HEV treatment.
